What Is Estradiol?
Bioidentical Estrogen Therapy · Last reviewed by the OPTML clinical team on April 29, 2026
Estradiol (17β-estradiol) is the predominant and most biologically active estrogen in premenopausal women, produced primarily by the ovaries. Bioidentical estradiol used in modern HRT is structurally identical to endogenous estradiol, distinct from synthetic conjugated equine estrogens (Premarin) used in the original WHI trial. Estradiol is available as oral tablets, transdermal patches, topical creams/gels, vaginal preparations, and pellets.
Physiology
Estradiol is produced principally by the granulosa cells of ovarian follicles in premenopausal women, with smaller contributions from peripheral aromatization of androgens. Levels fluctuate cyclically (50-400 pg/mL across the menstrual cycle) and decline progressively during perimenopause, reaching post-menopausal baseline (typically <30 pg/mL) by approximately age 51 in U.S. women.
Estradiol acts on estrogen receptors (ERα, ERβ) distributed throughout virtually every tissue: brain, bone, blood vessels, breast, uterus, urogenital tract, skin, and adipose. Its decline produces the recognizable cluster of menopausal symptoms.
Forms and Routes
| Form | Route | Notes |
|---|---|---|
| Estradiol hemihydrate | Oral tablet (daily) | First-pass hepatic metabolism, modestly higher VTE risk |
| Estradiol patch | Transdermal (twice weekly) | Bypasses liver, lower VTE risk; preferred for higher-risk patients |
| Estradiol cream / gel | Topical (daily) | Variable absorption; partner-transfer caution |
| Estradiol vaginal cream / tablet / ring | Local | Genitourinary symptoms; minimal systemic absorption |
| Estradiol pellet | Subcutaneous implant | 3-6 month duration; less dose flexibility |
Indications
- Vasomotor symptoms (hot flashes, night sweats), first-line therapy.
- Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms).
- Prevention of post-menopausal osteoporosis, particularly when initiated early.
- Premature ovarian insufficiency and surgical menopause.
- Quality-of-life: sleep, mood, cognition, joint pain, supported by clinical experience and quality-of-life endpoints in trials.
Why Pair Estradiol with Progesterone
In a woman with an intact uterus, unopposed estrogen drives endometrial proliferation and significantly increases the risk of endometrial hyperplasia and endometrial cancer. Estradiol should always be paired with progesterone (typically oral micronized progesterone) in women who have a uterus. Women who have had a hysterectomy may use estradiol alone.
Side Effects and Risks
- Breast tenderness (common in first 1-3 months).
- Headache, nausea, bloating.
- Breakthrough bleeding (especially in the first 6 months).
- Small absolute increase in VTE risk with oral preparations (transdermal not associated with same elevation).
- Modestly increased breast cancer risk with combined estrogen+progestin therapy used long-term; magnitude varies by formulation.
- Contraindicated in active breast/endometrial cancer, undiagnosed vaginal bleeding, recent VTE, active liver disease, and known thrombophilias without specialty oversight.
Estradiol vs. Conjugated Equine Estrogens
Premarin (CEE) is a mixture of estrogens isolated from pregnant mare urine, including some estrogen species not naturally found in humans. The original WHI trial used CEE (alone or with medroxyprogesterone). Bioidentical 17β-estradiol is the molecule produced by the ovaries and is what modern HRT generally prescribes.
Considering estradiol?
Tablet $99/mo · Topical cream $229/mo · Bioidentical · Physician-supervised.
Talk to a provider →References
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: WHI randomized trials. JAMA. 2017;318(10):927-938.
- Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and VTE Risk: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015;100(11):4012-4020.